Friday, August 7

Browsing: targetedMRimaging

Research

Exploring the in-vitro evaluation of folic acid-modified gadolinium nanoparticles in HEK-293, HeLa, and KB cancer cells for targeted-MR-imaging agent candidate

By NewsCancerAugust 7, 20260

World Health Organization. Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer. (2024).International Agency for Research on Cancer. Global Cancer Observatory: Cancer Today. https://gco.iarc.fr/today/en/data-sources-methods#mortality. (2022).Marko, A. J.…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

Reviewing the EMERALD-1 Trial of TACE With Durvalumab and Bevacizumab

Exploring the in-vitro evaluation of folic acid-modified gadolinium nanoparticles in HEK-293, HeLa, and KB cancer cells for targeted-MR-imaging agent candidate

Post-translational modifications in metabolic reprogramming: implications for metabolic therapy and immunotherapy in cancer

Browsing: targetedMRimaging

Exploring the in-vitro evaluation of folic acid-modified gadolinium nanoparticles in HEK-293, HeLa, and KB cancer cells for targeted-MR-imaging agent candidate

Reviewing the EMERALD-1 Trial of TACE With Durvalumab and Bevacizumab

Exploring the in-vitro evaluation of folic acid-modified gadolinium nanoparticles in HEK-293, HeLa, and KB cancer cells for targeted-MR-imaging agent candidate

Post-translational modifications in metabolic reprogramming: implications for metabolic therapy and immunotherapy in cancer

How pain treatment transformed cancer patient’s future

Reviewing the EMERALD-1 Trial of TACE With Durvalumab and Bevacizumab

Exploring the in-vitro evaluation of folic acid-modified gadolinium nanoparticles in HEK-293, HeLa, and KB cancer cells for targeted-MR-imaging agent candidate

Post-translational modifications in metabolic reprogramming: implications for metabolic therapy and immunotherapy in cancer

How pain treatment transformed cancer patient’s future

Latest Post

Reviewing the EMERALD-1 Trial of TACE With Durvalumab and Bevacizumab

Exploring the in-vitro evaluation of folic acid-modified gadolinium nanoparticles in HEK-293, HeLa, and KB cancer cells for targeted-MR-imaging agent candidate

Post-translational modifications in metabolic reprogramming: implications for metabolic therapy and immunotherapy in cancer

Subscribe to Updates

What's Hot

Browsing: targetedMRimaging